JPRN-jRCT2080224525已完成3 期
Cardiovascular Outcome trial of NN9535 (EX9536-4388)
ovo Nordisk Pharma Ltd.0 个研究点目标入组 350 人开始时间: 2019年1月16日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 45age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Overweight or obesity subject with high cardiovascular event risk
排除标准
- •Diabetes, Severe heart failure, History of pancreatitis, Severe psychological disorder, other
研究者
相似试验
已完成
3 期
A trial to Investigate the cardiovascular Safety of Oral Semaglutide in the Subjects with Type 2 Diabetes.CTRI/2017/02/007841ovo Nordisk India Private Ltd201
招募中
1 期
A Phase I Clinical Study of NS-025 in Healthy SubjectsJPRN-jRCT2031220474Higashioka Masaya122
未知
3 期
MK-0431/ONO-5435 Phase III Clinical Study - Long-term Treatment Study for Patients with Type 2 Diabetes MellitusType 2 Diabetes MellitusJPRN-jRCT2080220289ONO PHARMACEUTICAL CO.,LTD.
招募中
不适用
Cardiovascular Outcomes in Patients with Non-ST-Elevation Acute coronary syndrome with Negative Stress TestThe non-ST-elevation acute coronary syndrome (NSTE-ACS) patientsNon-elevation acute coronary syndrome1 year mortality rateCardiovascular OutcomesNegative Exercise stress testNegative Dobutamine stress echocardiography testTCTR20190118005Faculty of Medicine, Chiang Mai University265
招募中
1 期
A phase 1 study in patients with Fukuyama-type congenital muscular dystrophyFukuyama-type congenital muscular dystrophyJPRN-jRCT2031210252Toda Tatsushi12